{"commentary":{"count":60,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":28,"podcast":18,"x_thread":14},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04133636\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CARTITUDE-2","nct_id":"NCT04133636","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cartitude-2-nct04133636. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CARTITUDE-2","arms":[{"description":"Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A (Progressive disease post 1-3 prior lines of therapy), Cohort B (Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma \\[NDMM\\], standard risk \\[International Staging System Stage I/II\\] and post initial therapy); Cohort E(NDMM,transplant not planned, high risk disease) will first receive quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Enrollment is closed for Cohorts A,B,C,D,E and F. For US sites only: Part B:Cohort G (NDMM, transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel.","label":"JNJ-68284528","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-08-25","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":208,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"JNJ-68284528","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Daratumumab","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"68284528MMY2003: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-02-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)","timeFrame":"At least 1 year after JNJ-68284528 infusion on Day 1"},{"measure":"For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)","timeFrame":"At least 1 year after JNJ-68284528 infusion on Day 1"}],"references":[{"citation":"Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, Martin T, Suvannasankha A, De Braganca KC, Corsale C, Schecter JM, Varsos H, Deraedt W, Wang L, Vogel M, Roccia T, Xu X, Mistry P, Zudaire E, Akram M, Nesheiwat T, Pacaud L, Avivi I, San-Miguel J. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023 Jan 19;141(3):219-230. doi: 10.1182/blood.2022015526.","pmid":"36095849","type":"DERIVED"}],"start_date":{"date":"2019-11-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT04133636"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cartitude-2-nct04133636"}